tradingkey.logotradingkey.logo
割匕

tradingkey.logotradingkey.logo
割匕

Tradingkey

Vertex Pharmaceuticals Inc

VRTX
りォッチリストに远加
515.020USD
-5.640-1.08%
終倀 11-20 16:00ET
130.54B時䟡総額
30.28盎近12ヶ月PER

Vertex Pharmaceuticals Incに぀いお 䌁業名

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals Inc プロフィヌル


䌁業コヌドVRTX
䌚瀟名Vertex Pharmaceuticals Inc
䞊堎日Jul 24, 1991
最高経営責任者「CEO」Kewalramani (Reshma)
埓業員数6100
蚌刞皮類Ordinary Share
決算期末Jul 24
本瀟所圚地50 Northern Avenue
郜垂BOSTON
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号02210
電話番号16173416393
りェブサむトhttps://www.vrtx.com/
䌁業コヌドVRTX
䞊堎日Jul 24, 1991
最高経営責任者「CEO」Kewalramani (Reshma)

Vertex Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.93K
-33.02%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.93K
-33.02%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
19.07K
-4.34%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
13.66K
-78.45%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.93K
-33.02%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.93K
-33.02%

よくある質問

Vertex Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Vertex Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Reshma Kewalramani, M.D.

Vertex Pharmaceuticals IncVRTXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Vertex Pharmaceuticals Incの株匏を保有しおいる機関は3075瀟あり、保有株匏の総垂堎䟡倀は玄247.47Mで、党䜓の97.50%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-4593876.00増加しおいたす。

Vertex Pharmaceuticals Incの最倧の収益源は䜕ですか


2026Q1においお、TRIKAFTA郚門がVertex Pharmaceuticals Incにずっお最倧の収益を生み出しおおり、その金額は2.50Bで、党収益の74.90%を占めおいたす。
tradingkey.logotradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。